With Ver­tex and CRISPR some 30 pa­tients in, Ed­i­tas moves for­ward in sick­le cell pa­tients af­ter FDA lifts hold

With gene ther­a­pies for sick­le cell dis­ease prov­ing all the rage, one com­pa­ny is get­ting its FDA-im­posed chains re­moved.

Ed­i­tas Med­i­cine an­nounced Wednes­day that the FDA lift­ed a par­tial hold on an ear­ly-stage study for its sick­le cell ther­a­py. Reg­u­la­tors had placed the hold on the com­pa­ny’s ED­IT-301 pro­gram and asked it to de­vel­op a new po­ten­cy as­say, com­pa­ny spokesper­son Cristi Bar­nett tells End­points News. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER